• 1
    Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123126. MEDLINE
  • 2
    Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996; 271:15821586. MEDLINE
  • 3
    Nowak MA, Bonhoeffer S, Hill A, Boehme R, Thomas H, McDade H. Viral dynamics in hepatitis C infection. Proc Natl Acad Sci U S A 1996; 93:43984402. MEDLINE
  • 4
    Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, et al. Viral dynamics in human deficiency virus type 1 infection. Nature 1995; 373:117122. MEDLINE
  • 5
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with IFN alfa. Hepatology 1997; 26:226231. MEDLINE
  • 6
    Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10:761763. MEDLINE
  • 7
    Zeumen S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of IFN-alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366371. MEDLINE
  • 8
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of IFN-α therapy. Science 1998; 282:103107. MEDLINE
  • 9
    Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with two different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35:930936.
  • 10
    Zhu H, Nelson D, Crawford J, Liu C. Interferon alpha induced antiviral activity in hepatitis C viral replicon cell cultures [Abstract]. Hepatology 2001; 34:347A.
  • 11
    Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 hepatitis C virus. J Infect Dis 2000; 182:2835. MEDLINE
  • 12
    Layden JE, Reddy KR, Kozlowski M, Wiley TE, Neumann AU, Layden TJ. Differences in viral kinetic parameters in response to IFN treatment between African Americans and Caucasians infected with genotype 1 virus [Abstract]. Hepatology 2001; 34:417A.
  • 13
    Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. Racial differences in response to therapy with IFN in chronic hepatitis C. Hepatology 1999; 30:787793. MEDLINE
  • 14
    Kuhen KL, Samuel CE. Mechanism of IFN action: functional characterization of positive and negative regulatory domains that modulate transcriptional activation of the human RNA-dependent protein kinase PKR promoter. Virology 1999; 72:99349939.
  • 15
    Gale M Jr., Katze MG. Molecular mechanisms of IFN resistance mediated by viral-directed inhibition of PKR, the IFN induced protein kinase. Pharmacol Ther 1998; 78:2946. MEDLINE
  • 16
    Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC. Inhibition of the IFN-I inducible protein kinase PKR by HCV E2 protein. Science 1999; 285:107110. MEDLINE
  • 17
    Layden JE, Layden TJ, Levi-Drummer R, Reddy KR, Poulakos J, Neumann AU. Early viral kinetics of HCV-predicting treatment response after only 24 hours [Abstract]. Digestive Disease Week; DDW Program Book, AGA 2001; A-30.
  • 18
    Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, Mueller C, et al. Primary IFN resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358:12411242. MEDLINE
  • 19
    Jessner W, Stauber R, Gschwantler M, Hackl F, Munda-Steindl P, Datz C, Watkins-Riedel T, et al. Viral dynamics on pegylated IFN alfa-2a differs from standard IFN in patients infected with HCV genotype 1 [Abstract]. 8th International Symposium on Hepatitis C Virus and Related Viruses. 2001.
  • 20
    Neumann AU, Layden TJ, Reddy KR, Levi-Drummer R, Poulakos J. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response following consensus IFN treatment for chronic hepatitis C and is determined by genotype but not dose [Abstract]. Hepatology 2000: 32: 356A.
  • 21
    Zeuzem S, Hermann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. Gastroenterology 2001; 120:14381447. MEDLINE
  • 22
    Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:6591. MEDLINE
  • 23
    Bekkering FC, Stalgis C, McHutchison JG, Brouwer T, Perelson AS. Estimation of early hepatitis viral clearance in patients receiving daily IFN and ribavirin therapy using a mathematical model. Hepatology 2001; 33:419423. MEDLINE
  • 24
    Bergmann C, Layden JE, Levy-Drummer R, Layden TJ, Haagmans B, Neumann AU. Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during IFN-alpha therapy [Abstract]. Hepatology 2001; 34:345A.
  • 25
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680687. MEDLINE
  • 26
    Fukomoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, Lobeck H, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of hepatitis C early after orthotopic liver transplantation. Hepatology 1996; 24:13511354. MEDLINE
  • 27
    Chan J, O'Riordan K, Wiley TE. Amantadine's viral kinetics in hepatitis C virus infection. Am J Gastroenterol 2002 (in press).
  • 28
    Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, et al. Treatment of acute hepatitis C with IFN alfa-2b. N Engl J Med 2001; 345:14521457. MEDLINE
  • 29
    Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, Mor E, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831838. MEDLINE
  • 30
    Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, Marino IR. Interferon-alpha for prophylaxis of recurrent viral hepatitis in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65:8286. MEDLINE